Alnylam Pharmace. Stock
Price
Target price
€248.80
€248.80
4.140%
9.9
4.140%
€431.31
16:40 / Tradegate
WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alnylam Pharmace. Stock
Alnylam Pharmace. dominated the market today, gaining €9.90 (4.140%).
With 45 Buy predictions and not a single Sell prediction Alnylam Pharmace. is an absolute favorite of our community.
With a target price of 431 € there is a hugely positive potential of 73.23% for Alnylam Pharmace. compared to the current price of 248.8 €.
Our community identified positive and negative aspects for Alnylam Pharmace. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Alnylam Pharmace. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 4.140% | 2.181% | -7.331% | -13.661% | -29.486% | 36.514% | 56.451% |
| Ligand Pharmaceuticals | 0.000% | 0.000% | 2.308% | 129.310% | 60.241% | 336.066% | 155.646% |
| United Therapeutics | 0.020% | -0.705% | -2.802% | 79.183% | 8.776% | 110.032% | 196.051% |
| Ionis Pharmaceuticals Inc. | -0.860% | 4.563% | -27.823% | 38.254% | -26.825% | 40.124% | 53.915% |
Comments
Alnylam Pharmaceuticals (ALNY) had its price target lowered by JPMorgan Chase & Co. from $420.00 to $400.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (ALNY) had its price target lowered by Bank of America Corporation from $460.00 to $410.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (ALNY) had its price target raised by HC Wainwright from $470.00 to $485.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat